AK-3280 is under clinical development by Shanghai Ark Biopharmaceutical and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AK-3280’s likelihood of approval (LoA) and phase transition for Idiopathic Pulmonary Fibrosis took place on 10 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AK-3280 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AK-3280 is under development for the treatment of interstitial lung disease (idiopathic pulmonary fibrosis), progressive fibrosing interstitial lung diseases (PF-ILD), liver fibrosis and hypertrophic scars. The drug candidate is a second generation pirfenidone analog. It is administered orally formulated as tablet and also formulated as cream for topical use. It is a new molecular entity.
Shanghai Ark Biopharmaceutical overview
Shanghai Ark Biopharmaceutical (Ark Biopharma) operates as a biopharmaceutical company. The company engages in discovery and development of innovative therapeutics to address respiratory viral infection and viral hepatitis. Ark Biopharma is headquartered in Pudong, Shanghai, China.
Quick View AK-3280 LOA Data
|Highest Development Stage|